![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
EINDHOVEN, the Netherlands, June 26, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to...
ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage...
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, the...
ONWARD® Medical berichtet über das 1. Quartal 2024 und die bisherigen Höhepunkte des Jahres Ergebnisse der Up-LIFT-Zulassungsstudie in Nature Medicine veröffentlicht Einreichung des...
Nature Medicine published Up-LIFT pivotal trial results Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital EINDHOVEN, the Netherlands, May 23...
ONWARD® Medical organise une téléconférence pour partager les détails relatifs à son étude clinique Up-LIFT et à sa publication dans la revue Nature Medicine La revue Nature Medicine a publié...
ONWARD® Medical veranstaltet Webcast zu Einzelheiten der Up-LIFT-Studie und der aktuellen Veröffentlichung in Nature Medicine Ergebnisse der Up-LIFT-Zulassungsstudie in Nature Medicine...
Nature Medicine hebt signifikante Verbesserung der Hand- und Armfunktion nach einer Rückenmarksverletzung durch die ONWARD® ARC-EX® Therapie hervor ARC Therapy™ hat sich in einer globalen...
ONWARD® Medical to Host Webcast to Share Details from its Up-LIFT Trial and Yesterday’s Nature Medicine Publication Nature Medicine published Up-LIFT pivotal trial results Company will...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -1.20967741935 | 4.96 | 5 | 4.81 | 17651 | 4.87995434 | DE |
4 | -0.4 | -7.54716981132 | 5.3 | 5.6 | 4.76 | 27559 | 5.09762873 | DE |
12 | -0.05 | -1.0101010101 | 4.95 | 6.18 | 4.51 | 66246 | 5.31274269 | DE |
26 | 1.8 | 58.064516129 | 3.1 | 6.58 | 1.85 | 91838 | 4.97893089 | DE |
52 | -0.34 | -6.48854961832 | 5.24 | 6.58 | 1.85 | 51596 | 4.85056818 | DE |
156 | -8.12 | -62.3655913978 | 13.02 | 13.28 | 1.85 | 25050 | 5.62667953 | DE |
260 | -8.12 | -62.3655913978 | 13.02 | 13.28 | 1.85 | 25050 | 5.62667953 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions